Consequently, cost-effective improvement in the management of hypertension is crucial.
Data from large clinical trials demonstrate that it is possible to achieve adequate BP control in patients with hypertension. [7] [8] [9] However, since the pathogenesis of hypertension is typically multifactorial and involves counterregulatory mechanisms, it is frequently difficult to achieve this control using therapy directed at a single factor or mechanism. 10, 11 In most clinical trials, adequate BP control was achieved only when combination therapy involving 2 or more antihypertensive agents was employed. 7, 9, [12] [13] [14] [15] These findings have led the American Society of Hypertension to conclude that at least 75% of patients with hypertension will require 2 or more antihypertensive agents in order to achieve contemporary BP targets. 10 Moreover, it is estimated that at least 25% of patients with hypertension will require 3 or more agents in order to achieve these targets. 11 Single-pill fixed-dose antihypertensive combination therapy simplifies the treatment regimen and may thus provide a convenient treatment option for patients. 16 Such therapy has been shown to be significantly more effective in achieving BP control at 1 year than either free-drug combination therapy (i.e., multiple-pill therapy) or monotherapy. 17 Because some single-pill fixed-dose combination therapies for hypertension are available only as brand-name drugs, drug costs may be
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higher for such therapies when compared with the individual generic components. 18, 19 The intent of this commentary is to present information on the enhanced efficacy of fixed-dose combination therapy and the potential to offset increases in drug cost, ultimately leading to a reduction in overall health care expenses.
■■ Adherence and Persistence with Antihypertensive Therapy
Because hypertension is a chronic, life-long disorder, longterm adherence to and persistence with pharmacotherapy are crucial in achieving and maintaining BP control. [20] [21] [22] [23] In a longitudinal evaluation of adherence and persistence using an electronic medication event monitor, about half of the patients who were prescribed an antihypertensive drug had stopped taking it within 1 year, and on any day, patients who were still engaged with the drug dosing regimen omitted about 10% of the scheduled doses ( Figure 1 ). 24 As a result, nonadherence to and/or nonpersistence with the therapeutic regimen continue 24 tion therapy was shown to reduce the risk of nonadherence by 24% (95% CI: 19%-29%) compared with free-drug combination therapy. 39 Similarly, in a subsequent retrospective cohort evaluation of 14,449 patients with hypertension, fixed-dose combination therapy was found to increase multivariateadjusted adherence and persistence at 1 year by 22.1% (95% CI: 19.9%-24.1%) and by 42.5% (95% CI: 40.6%-44.5%), respectively, compared with free-drug combination therapy. 26 In a recent meta-analysis published in 2011, patients receiving fixed-dose combination therapy were found to have 13.3% (95% CI: 8.26%-18.35%) greater adherence and were more than twice as likely to be persistent (risk ratio: 2.13; 95% CI: 1.11-4.09) with antihypertensive treatment than patients receiving free-drug combination therapy. 44 Although fixed-dose combination therapies simplify a patient's treatment regimen, these combinations have some disadvantages: branded combinations may be more expensive than equivalent free-drug combinations; the duration of action of individual components may not be equivalent; and the use of fixed-dose combinations results in less flexibility in modifying the doses of individual components. 47 Furthermore, patients with higher adherence may be different compared with those who had lower adherence. Patients with better adherence may have healthier lifestyle choices and higher social-economic status, which are likely to be associated with lower cardiovascular risk.
■■ Role of Fixed-Dose Combination Therapy in BP Control
Consistent with these increases in adherence and/or persistence, fixed-dose combination therapy has been shown to be more effective than free-drug combination therapy in reducing BP and achieving the goals recommended in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). 5 In a prospective, one-way, crossover evaluation, 196 patients with hypertension were treated using dose-equivalent multiple-pill and single-pill combination therapy for consecutive 3-month periods. 45 Adherence was assessed using tablet counts, and efficacy was assessed using daily morning mean BP during the final month of each treatment period. 45 Adherence was significantly greater and morning mean BP significantly lower during the single-pill phase of the trial, with improvement in BP control during this phase directly related to the increase in adherence. 45 Likewise, multivariate-adjusted analysis of NHANES data from 2005 to 2010 found that single-pill combination therapy was 55% (95% CI: 20%-100%) more effective than monotherapy in achieving JNC 7 BP goals, whereas multiple-pill therapy was only 26% (95% CI: 3%-55%) more effective than monotherapy in achieving these goals. 5 In another analysis of the latest NHANES data (2009 to 2010), patients with hypertension who received single-pill combination therapy were 9.5% more likely to achieve JNC 7 BP goal than patients with hypertension who received multiple-pill therapy (68.8% vs. 59.3%, respectively). 5 to be major risk factors for suboptimal BP control; however, these risk factors are modifiable. 21 In a cross-sectional evaluation, patients who were nonadherent to antihypertensive pharmacotherapy were significantly more likely than patients who were adherent to have uncontrolled BP (age-gender adjusted odds ratio [OR]: 27.2; 95% confidence interval [CI]: 17.4-42.6). 20 In a prospective evaluation of patients with mild to moderate hypertension who were randomized to treatment with either an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin receptor blocker (ARB), a calcium channel blocker, a beta blocker, or a diuretic, decreases in both systolic and diastolic BP were proportional to the rate of persistence with treatment and closely related to the tolerability profile of the agent employed. 21 Multiple analyses have clearly demonstrated that a lack of adherence and/or persistence significantly increases the risk of cardiovascular events, emergency department visits, and hospitalizations. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] In an analysis of registry data from 18,806 patients with hypertension, low adherence was associated with a 38% (95% CI: 4%-60%) increase in the relative risk of cardiovascular events. 28 In a cohort evaluation of 242,594 patients with newly treated hypertension, very low adherence was associated with a 24% increase (95% CI: 18%-30%) in the risk of coronary events and a 23% increase (95% CI: 16%-29%) in the risk of cerebrovascular events. 29 In another cohort evaluation of 59,647 patients with newly treated hypertension, low adherence was associated with increased risks of coronary artery disease (OR: 1.07; 95% CI: 1.00-1.13), first cerebrovascular events (OR: 1.13; 95% CI: 1.03-1.25), and first chronic heart failure (OR: 1.42; 95% CI: 1.27-1.58). 30 Similarly, in a cohort evaluation of 14,449 patients receiving combination therapy for hypertension, adjusted prevalence of hypertension-related office visits, emergency department visits, and hospitalizations increased 0.4% (95% CI: 0.1%-0.7%), 0.2% (95% CI: 0.1%-0.2%), and 0.3% (95% CI: 0.2%-0.4%), respectively, for each 10% decrease in adherence as indicated by medication possession ratios. 26 In another cohort evaluation of 381,661 patients receiving combination therapy for hypertension, the adjusted incidence rate ratios of all-cause (1.29; 95% CI: 1.24-1.33) and cardiovascular (1.36; 95% CI: 1.30-1.43) hospitalizations were increased in patients who were nonpersistent versus those who were persistent. 33 Long-term adherence decreases as the number of drugs in or the complexity of the therapeutic regimen increases. 35, 36 Because fixed-dose combination therapy reduces pill count, it may be a convenient option for patients who require more than 1 agent to treat hypertension or who require additional medications for comorbid conditions. 37, 38 Multiple evaluations have demonstrated that reducing pill burden and simplifying the therapeutic regimen through the use of single-pill fixed-dose combination therapy improves adherence and/or persistence. 26, [39] [40] [41] [42] [43] [44] [45] [46] In a meta-analysis published in 2007, which included data from 4 hypertension trials, fixed-dose combina-Fixed-dose combination therapy has been shown not only to be more effective in lowering BP than either free-drug combination or monotherapy, but also to increase adherence and persistence with the antihypertensive regimen. 5, 26, 39, 40, [42] [43] [44] [45] 48 This enhanced efficacy and persistence have been shown to reduce cardiovascular risk, with a resultant decrease in the incidence of cerebrovascular disease, coronary disease, chronic heart failure, and death. 1, 30, [48] [49] [50] [51] In a retrospective cohort evaluation of 83,267 patients with newly treated hypertension and no evidence of cardiovascular or cerebrovascular disease at initiation of therapy who were followed for up to 5.5 years, the multivariate-adjusted risk of cerebrovascular disease after at least 1 year of treatment was reduced by 22% (95% CI: 13%-30%) in patients with high adherence (≥ 80%) versus those with low adherence (< 80%). 49 Similarly, in a retrospective cohort evaluation of 49,479 patients with hypertension and no evidence of prior stroke who were followed for up to 5 years, the multivariate-adjusted risk of stroke was reduced by 8% (95% CI: 4%-13%), and the multivariate risk of death was reduced by 7% (95% CI: 4%-10%) in patients with high adherence (≥ 80%) versus those with low adherence (< 80%) during the follow-up period. 50 Given the mean medication refill adherence of 67% in this latter evaluation, increasing adherence by only 1 pill per week for a once-a-day antihypertensive regimen could reduce mortality risk by 7%. 50 One limitation of these evaluations is that they assessed the effects of adherence and not the effects of fixed-dose combination therapy, on cardiovascular risk. Consequently, the effects of fixed-dose combination therapy on cardiovascular risk can only be inferred from the effects on adherence. A retrospective cohort evaluation of 28,594 patients with hypertension has recently assessed the direct effects of fixed-dose (n = 9,929) versus free-drug (n = 18,665) combination therapy on cardiovascular risk. 51 In this evaluation, fixeddose combination therapy reduced the risk of cardiovascular events compared with free-drug combination therapy by 27% (95% CI: 24%-30%) before and by 26% (95% CI: 23%-30%) after correcting for confounding variables (Figure 2 ). 51 
■■ Cost of Hypertension Management
Assessing the cost of hypertension management is a complicated process that involves numerous types of expenses and multiple payers with potentially conflicting interests (e.g., individual patients, private insurance companies, government, and society.) As such, these costs can be only briefly summarized 
Prevalence of First Cardiovascular Event in Patients Initiated on Either a Fixed-Dose Combination or a Free-Drug Combination Antihypertensive Regimen and Followed for a Minimum of 5 Years

51
PCI = percutaneous coronary intervention; ACS = acute coronary syndrome; CABG = coronary artery bypass graft; MI = myocardial infarction; HF = heart failure; TIA = transient ischemic attack.
here. Direct costs of hypertension include the costs of prescribed medications, home health care, outpatient care, emergency department visits, and hospital admissions. 3 In addition, indirect costs of hypertension include lost productivity due to morbidity and premature mortality, where morbidity costs represent the value of lost work among currently employed individuals, lost work among individuals too sick to work, and lost home productivity, and premature mortality costs represent the value of forgone earnings. 3, 6 In 2010, annual direct and indirect costs (in 2008 dollars) for hypertension in the United States were estimated to be $70 billion and $24 billion, respectively, when considering hypertension alone, and $131 billion and $25 billion, respectively, when considering hypertension in addition to the component cost of other cardiovascular disorders directly attributable to hypertension. 6 A decrease in cardiovascular events leads to reduced health care utilization. In separate evaluations, patients with hypertension who were prescribed fixed-dose combination therapy had fewer mean annual physician visits for a primary cardiovascular diagnosis (0.2 vs. 0.9; P < 0.001) 52 and fewer referrals to a hypertension, cardiology, or general medical outpatient department over a minimum 5-year follow-up period (18.8% vs. 23.7%). 51 Furthermore, increased adherence to antihypertensive therapy and/or use of fixed-dose combination therapy has been shown to decrease emergency department visits, 26, 31, 42 hospitalizations, 25, 26, 31, 42 and hospital length of stay. 30, 53 In a retrospective cohort evaluation, the annual number of inpatient hospital days decreased by 8.2% (P = 0.01) and the annual number of absent work days decreased by 12.5% (P = 0.03) for every 10% increase in adherence in patients with hypertension who were in the top 3 quintiles of medical expenditure at baseline. 53 Likewise, in another retrospective cohort evaluation, the incidence rate ratios of cardiovascular and all-cause emergency department visits and cardiovascular and all-cause hospitalizations were significantly reduced in patients with hypertension who were treated with fixed-dose combination therapy compared with free-drug combination therapy (Figure 3) . 42 This reduction in health care utilization with fixed-dose combination therapy decreases the overall cost of medical services. Numerous evaluations have found that diseasespecific and/or total medical services costs are lower in patients with hypertension who are treated with fixed-dose therapy compared with those who use free-drug combination therapy. 26, 40, 42, 44, 46, 52, 54, 55 In separate analyses, patients receiving fixed-dose rather than free-drug combination therapy had lower annual costs for hypertension-related services ($188 less; P = 0.012), 26 ambulatory services ($526 less; P < 0.001), hospital services ($76 less; P = 0.502), and other services, such as Medicare crossover costs ($827 less; P < 0.001), 54 and lower total annual costs for medical services, including prescription and medical costs ($474 less; P = 0.001). 40 In addition, a metaanalysis of data from trials assessing fixed-dose versus free- 
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All-cause drug combination therapy found that annual costs in 2009 dollars for hypertension-or cardiovascular-related care ($710 less; 95% CI: $118-$1,302) and all-cause care ($2,039 less; 95% CI: $1,031-$3,048) were significantly lower in patients with hypertension who received fixed-dose combination therapy rather than free-drug therapy. 44 In a recent study assessing the impact of fixed-dose (2-pill) versus free-dose (3-pill) triple-combination therapy on adherence, clinical, and economic outcomes, patients receiving fixed-dose therapy were more likely to be adherent (P < 0.001) and less likely to discontinue treatment (P < 0.001) across each of 3 cohorts (ARB, beta blocker, and ACE inhibitor cohorts). Fixed-dose therapy resulted in a significantly lower adjusted risk of cardiovascular events (hazard ratio = 0.76, P = 0.005) in the beta blocker cohort only and total adjusted health care costs were significantly lower for fixeddose therapy in the beta blocker cohort only (cost ratio = 0.74 overall, P < 0.01 and 0.71 hypertension-attributable, P < 0.01). 56 These reductions in the overall cost of medical services may offset any potential increase in drug costs associated with fixed-dose combination therapy. Studies assessing differences in drug costs between fixed-dose and free-drug combination antihypertensive treatments have yielded conflicting results, potentially due to differences in study design, patient population, and drugs being evaluated. Depending upon the specific evaluation, drug costs for fixed-dose combination therapy have been reported to be less expensive than, 40 ,52,54,55 comparable to, 44 or more expensive than 18, 42 free-drug combination therapy. For example, a multivariate analysis of data from nearly 600,000 patients who were started on combination therapy for hypertension found that the adjusted change from baseline in the cost of hypertension drugs over the 6-month follow-up period was $53 greater (95% CI: $51-$55) with fixed-dose versus free-drug combination therapy, but that the adjusted change in overall drug costs (fixed-dose: $5 more; 95% CI: $2 less-$13 more) was not significantly different between the 2 treatment groups. 42 In contrast, the previously mentioned meta-analysis of fixed-dose versus free-drug combination therapy trials found no significant difference with respect to hypertension-or cardiovascular-related drug costs (fixed-dose: $70 less; 95% CI: $83 more-$224 less) but significantly lower overall drug costs with fixed-dose versus free-drug combination therapy ($606 less; 95% CI: $376 more-$835 less). 44 Even in evaluations finding greater drug costs with fixeddose combination therapy, total health care costs, including medical services, were comparable, if not lower, with fixed-dose versus free-drug combination therapy. 42, 51 In an evaluation, a $53 increase in multivariate-adjusted hypertension-related drug costs with fixed-dose combination therapy was more than offset by a $208 decrease in multivariate-adjusted all-cause medical services costs. 42 Overall, use of fixed-dose combination therapy was found to reduce multivariate-adjusted total health care costs by 12.5% (P < 0.003) in one analysis 54 and by 24.4% (P < 0.001) in another. 55 ■■ Fixed-Dose, Triple-Drug Combination Therapy The prior evaluations of fixed-dose combination therapy primarily assessed dual-drug combinations. However, many patients require more than 2 drugs to achieve BP control. 7, 12, 13, 15 In these patients, the addition of 1 or more individual drugs to a dual-drug combination increases the complexity of the therapeutic regimen, potentially negating some of the clinical and economic benefits of the dual-drug combination. In order to address this issue, randomized, double-blind, active-controlled clinical trials have recently evaluated the short-term (8-to 12-week) safety and efficacy of 3 triple-drug combinations: (1) valsartan, amlodipine, and hydrochlorothiazide; (2) olmesartan, amlodipine, and hydrochlorothiazide; and (3) aliskiren, amlodipine, and hydrochlorothiazide. [57] [58] [59] In each of these trials, the triple-drug combination was well tolerated and more effective at lowering BP and achieving contemporary BP goals than any of the corresponding-component dual-drug combinations. In an open-label extension of the randomized trial with olmesartan, amlodipine, and hydrochlorothiazide, all study participants were switched to the triple-drug combination at the conclusion of their 12-week double-blind treatment period and were followed for an additional 40 weeks. 60 No new safety concerns were identified, and 55% and 64% of study participants achieved their BP goal within 2 weeks of starting and by the end of the open-label period/early termination, respectively. Mean BP reduction at the end of the open-label period/ early termination was comparable with that seen in study participants receiving triple-drug therapy during the double-blind treatment period, demonstrating the safety, antihypertensive efficacy, and durability of this triple-drug combination. 60 In the open-label study evaluating aliskiren, amlodipine, and hydrochlorothiazide, this triple-combination therapy was shown to be well tolerated and efficacious as a treatment for up to 54 weeks in patients with hypertension. 61 As a result of these evaluations, the U.S. Food and Drug Administration has approved all 3 of these triple-drug combinations for the management of hypertension as single-pill fixed-dose formulations in patients not controlled on dual therapy. These triple-drug combinations are Exforge HCT (valsartan, amlodipine, and hydrochlorothiazide, produced by Novartis Pharmaceuticals Corporation, East Hanover, NJ); Tribenzor (olmesartan, amlodipine, and hydrochlorothiazide by Daiichi Sankyo, Inc., Parsippany, NJ); and Amturnide (aliskiren, amlodipine, and hydrochlorothiazide, also from Novartis Pharmaceuticals). Based on the proven beneficial effects of fixed-dose dual-combination treatments in a real-world environment, these triple-combination preparations may prove to be useful and cost-effective additions for the treatment of hypertension.
■■ Conclusions/Perspectives
Most patients with hypertension will require combination therapy to achieve contemporary BP goals. In these patients, use of 
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single-pill fixed-dose preparations simplifies the therapeutic regimen and has been shown to improve adherence and persistence. Compared with patients who receive free-drug combination therapy, patients who receive single-pill fixed-dose combinations have been shown to be more likely to achieve BP goal, thereby reducing the risk of cardiovascular events. In addition, data suggest that outpatient and emergency department visits, hospitalization frequency, and duration of hospitalization are reduced in patients receiving fixed-dose combination therapy, and that these reductions in health care utilization appear to yield cost savings that, at a minimum, seem to offset any potential increase in drug cost. Consequently, use of single-pill fixed-dose combinations rather than free-drug combinations in patients with hypertension may be both clinically and economically beneficial. Although less well studied, triple-drug combinations have the potential to provide even greater economic benefits than dual-drug combinations; however, additional economic evaluations are needed.
